Engage
Most organizations facing a complex commercial, analytical, or strategic decision don't need a consulting report. They need a senior operator who has been inside the problem before, someone who can read the situation quickly, apply rigorous analysis, and lead the decision-making process rather than merely inform it.
That is what fractional leadership is. Not advice delivered from the outside. Embedded senior judgment applied to a specific problem over a defined period, with the accountability that comes from having skin in the outcome, not just the recommendation.
TVG Strategy engages in three practice areas where that combination of analytical rigor and operational experience produces the most durable value.
The deliverable is not a report. It is clarity and momentum.
Life Sciences Product and Brand Lifecycle Optimization
For organizations navigating launch, growth, decline, or repositioning across pharmaceutical, biotech, medical device, diagnostic, and biologics categories.
The most expensive moment in a product's commercial life is the one where the market signal is misread, where a launch is declared successful before adoption is real, where a decline is managed rather than reversed, or where a repositioning is executed without the field-level intelligence to make it land. These are not strategy failures. They are execution failures that strategy alone cannot fix.
Fractional leadership in this practice area means being inside the commercial decision at the point where the data, the market access question, and the field execution challenge converge, bringing the judgment that comes from nineteen product launches across five therapy sectors to the specific problem at hand. The engagement looks different depending on whether the organization is preparing a launch, managing a lifecycle inflection, or rebuilding commercial momentum after a setback.
Methodology: Commercial strategy, market access architecture, KOL engagement, field force effectiveness, launch sequencing, and lifecycle management drawn from 19 product launches across specialty pharma, medical devices, diagnostics, biologics, and neuromodulation.
Commercial Real Estate Investment & Use Decision Analysis
For investors, operators, developers, occupiers, and organizations making significant real estate decisions across retail, office, industrial, and multifamily asset classes.
Real estate decisions are irreversible in a way that most strategic decisions are not. The capital is committed, the lease is signed, the asset is acquired, and the quality of the analysis that preceded that moment either compounds or costs for years. Most organizations bring legal and financial counsel to these decisions as a matter of course. Fewer bring the analytical discipline to read the market signal correctly before the decision is made.
Fractional leadership in this practice area means applying CCIM-grade investment and use analysis to the specific decision at hand, whether that is an acquisition underwrite, a disposition strategy, a portfolio repositioning, or an occupancy decision for an organization entering or exiting a market. The engagement is grounded in primary data from institutional sources and structured around the question the client actually needs answered, not the question the data most easily supports.
Methodology: CCIM designation curriculum analytical framework applied to investment and use decisions across retail, office, industrial, and multifamily asset classes. Primary data sourced from U.S. Census Bureau, BLS, Federal Reserve, and institutional market data.
AI Strategy and Organizational Readiness
For organizations deploying, evaluating, or governing artificial intelligence systems, and for leadership teams that need to make consequential decisions about AI before the consequences of not deciding become irreversible.
The governance gap in AI is not a technology problem. It is a leadership problem. Organizations are deploying systems that are extraordinarily fluent and structurally opaque, systems that can describe a situation accurately and diagnose it incorrectly, and whose errors are precisely as convincing as their correct outputs. The leaders responsible for governing these systems often lack the analytical framework to distinguish between what the system is producing and what the organization actually needs from it.
Fractional leadership in this practice area means applying the Double Diamond+ innovation framework and human-centered design thinking to the specific AI challenge at hand, whether that is building a governance architecture, evaluating an AI investment, assessing organizational readiness for deployment, or developing the decision-making framework a board or executive team needs to govern AI with confidence rather than deference.
Methodology: Double Diamond+ innovation methodology, human-centered design thinking, and AI governance architecture. Applied across commercial strategy, life sciences, and organizational leadership contexts.
How Engagement Works
Engagements are structured around the problem, not a standardized service offering. Some situations call for a defined project, a specific deliverable over a specific timeline. Others call for an ongoing retainer, consistent access to senior judgment as a decision evolves over weeks or months. The structure depends on what the client actually needs, not on what is easiest to package.
Every engagement begins with a direct conversation, no intake form, no discovery questionnaire, no proposal before the problem is understood. The first conversation is diagnostic: what is the decision, what is the timeline, what does good look like on the other side, and is fractional leadership the right model for this situation. If it is not, that will be said directly.
The buyer is typically a senior executive, a board, or an organization facing a decision that requires both analytical rigor and operational experience simultaneously. The engagement works best when the client has a real problem, a defined timeline, and the organizational authority to act on what the analysis produces.
Every engagement begins with a direct conversation. No intake form. No proposal before the problem is understood.
Who This Is For
Life sciences organizations, emerging biotech, specialty pharma, medical device companies, and health systems that are navigating a launch, lifecycle inflection, or commercial rebuild where the stakes are high and the margin for misreading the market is thin.
Real estate investors, developers, occupiers, and portfolio managers who need investment-grade analytical rigor applied to a specific acquisition, disposition, or occupancy decision before the capital is committed.
Executive teams and boards facing consequential AI decisions, deployment, governance, risk assessment, or organizational readiness, who need a senior operator with a strategic framework, not a technology vendor with a product to sell.
Start the Conversation
If you are facing a decision that fits one of these practice areas and want to understand whether fractional leadership is the right model for your situation, the right next step is a direct conversation.
Reach out through the Contact page. Describe the problem briefly, one paragraph is enough to determine whether it makes sense to talk. If it does, we will find time quickly.